OverviewSuggest Edit

Evotec is a drug discovery alliance and development partnership company. It provides pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capital firms with drug discovery solutions in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates, and consulting arrangements. The company specializes in the areas of neuroscience, diabetes, and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, and fibrosis.

TypePublic
Founded1993
HQHamburg, DE
Websiteevotec.com
Employee Ratings3.1

Latest Updates

Employees (est.) (Dec 2020)3,572(+4%)
Revenue (FY, 2020)€509.9 M(+15%)
Share Price (Jun 2021)€35.3(+2%)
Cybersecurity ratingBMore

Key People/Management at Evotec

Werner Lanthaler

Werner Lanthaler

Chief Executive Officer
Craig Johnstone

Craig Johnstone

Chief Operating Officer
Enno Spillner

Enno Spillner

Chief Financial Officer
Cord Dohrmann

Cord Dohrmann

Chief Scientific Officer
Volker Braun

Volker Braun

SVP, Head of Global Investor Relations & ESG
Wolfgang Plischke

Wolfgang Plischke

Chairman of the Supervisory Board
Show more

Evotec Office Locations

Evotec has offices in Hamburg, Göttingen, Köln, Planegg and in 8 other locations
Hamburg, DE (HQ)
Essener Bogen 7
Göttingen, DE
Marie-Curie-Straße 7
Köln, DE
Nattermannallee 1/S20
Planegg, DE
19A Am Klopferspitz
Orth an der Donau, AT
Uferstraße 15
Lyon, FR
40 Avenue Tony Garnier
Show all (12)

Evotec Financials and Metrics

Evotec Revenue

Embed Graph
View revenue for all periods
Evotec's revenue was reported to be €509.92 m in FY, 2020 which is a 14.2% increase from the previous period.
EUR

Revenue (FY, 2020)

509.9m

Revenue growth (FY, 2019 - FY, 2020), %

14.2%

Gross profit (FY, 2020)

134.7m

Gross profit margin (FY, 2020), %

26.4%

Net income (FY, 2020)

6.3m

EBIT (FY, 2020)

48.5m

Market capitalization (11-Jun-2021)

5.8b

Closing stock price (11-Jun-2021)

35.3

Cash (31-Dec-2020)

422.6m

EV

5.9b
Evotec's current market capitalization is €5.8 b.
Annual
EURFY, 2018FY, 2019FY, 2020

Revenue

375.4m446.4m509.9m

Revenue growth, %

46%19%14%

Cost of goods sold

263.4m313.5m375.2m

Gross profit

112.0m132.9m134.7m
Quarterly
EURQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

79.0m94.8m96.3m103.8m103.2m114.3m119.4m111.6m129.4m

Cost of goods sold

60.5m63.0m62.9m72.2m71.1m79.3m86.1m91.8m93.3m

Gross profit

18.5m31.8m33.4m31.7m32.1m35.0m33.3m19.8m36.1m

Gross profit Margin, %

23%34%35%30%31%31%28%18%28%
Annual
EURFY, 2017FY, 2018FY, 2019FY, 2020

Cash

67.0m109.1m277.0m422.6m

Accounts Receivable

45.6m45.9m82.3m79.0m

Prepaid Expenses

8.6m8.5m9.2m

Inventories

9.0m5.7m10.7m13.6m
Quarterly
Annual
EURFY, 2018FY, 2019FY, 2020

Net Income

84.1m37.2m6.3m

Depreciation and Amortization

31.3m48.8m14.1m

Inventories

(283.0k)(1.4m)(3.6m)

Accounts Payable

5.0m(2.0m)2.2m
Quarterly
EURQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

3.5m17.9m52.3m13.1m10.7m29.7m17.1m7.3m5.8m

Cash From Operating Activities

4.1m71.2m128.7m(13.1m)(11.0m)1.2m27.1m(7.0m)20.8m

Purchases of PP&E

(6.2m)(2.7m)(20.7m)(5.8m)(14.4m)(20.4m)(16.3m)(28.7m)(55.3m)

Cash From Investing Activities

(7.5m)(13.6m)(17.9m)3.7m5.4m(58.6m)(13.5m)(53.2m)(82.9m)
EURFY, 2017

Debt/Equity

0.6 x

Debt/Assets

0.3 x

Financial Leverage

2 x
Show all financial metrics

Evotec Operating Metrics

Evotec's New Customers was reported to be 315 in FY, 2020. Evotec's Customers was reported to be 829 in FY, 2020.
FY, 2017FY, 2018FY, 2019FY, 2020

Products

80100100150

Projects

40606080

Customers

760707769829

New Customers

611263283315
Show all operating metrics

Evotec Acquisitions / Subsidiaries

Company NameDateDeal Size
Just-Evotec BiologicsMay 20, 2019$90 m
AptuitJuly 30, 2017$300 m
CyprotexOctober 26, 2016£55.7 m
EuprotecMay 28, 2014$3.2 m
Bionamics GmbHMarch 24, 2014
Cell Culture Service GmbHJanuary 03, 2013€1.2 m
Compound FocusJune 01, 2011
KINAXO BiotechnologiesApril 19, 2011
Develogen AGJuly 14, 2010
Evotec (India) Private LtdAugust 31, 2009
Show more

Evotec Revenue Breakdown

Embed Graph

Evotec revenue breakdown by business segment: 77.9% from EVT Execute and 22.1% from EVT Innovate

Evotec revenue breakdown by geographic segment: 18.8% from United Kingdom, 7.4% from France, 49.5% from Unites States, 15.5% from Others and 8.8% from Germany

Human Capital Metrics

Embed Graph
Show all human capital metrics

Evotec Cybersecurity Score

Cybersecurity ratingPremium dataset

B

80/100

SecurityScorecard logo

Evotec Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Evotec Online and Social Media Presence

Embed Graph

Evotec News and Updates

Evotec partners with CEBINA to launch Danube Labs, a partnership to develop cutting edge biotechnology projects sourced from Central and Eastern European Universities and Research Institutions

CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the launch of Danube Labs, a partnership with Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) to fast-track early-stage academic research to drug discovery and development. The joint project, …

Autobahn Labs incubator announces partnership with Cold Spring Harbor Laboratory to advance novel science to the clinic

Autobahn Labs, an early-stage drug discovery incubator, today announced a new strategic venture collaboration with Cold Spring Harbor Laboratory (CSHL). Together with Autobahn Labs, CSHL will identify promising research programs with therapeutic potential and partner to form promising new drug disco…

Evotec SE reports results for the first quarter 2021 and provides corporate update

Evotec today announced the financial results and corporate updates for the first quarter 2021

Evotec launches "beLAB1407" to accelerate translational research from the UK's academic life science ecosystem in collaboration with Bristol Myers Squibb

Evotec announced today that the Company, together with Bristol-Myers Squibb Company (NYSE: BMY), has launched beLAB1407, a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the UK’s top-tier academic institutions

Evotec SE to announce results for the first quarter 2021 on 11 May 2021

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) will announce its financial results for the first quarter of 2021 on Tuesday, 11 May 2021.

Evotec and the GCKD study enter into strategic collaboration to build a unique molecular patient database

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and the University Hospital Erlangen today announced a partnership regarding molecular analyses of biospecimens from the German Chronic Kidney Disease (“GCKD”) cohort study
Show more

Evotec Frequently Asked Questions

  • When was Evotec founded?

    Evotec was founded in 1993.

  • Who are Evotec key executives?

    Evotec's key executives are Werner Lanthaler, Craig Johnstone and Enno Spillner.

  • How many employees does Evotec have?

    Evotec has 3,572 employees.

  • What is Evotec revenue?

    Latest Evotec annual revenue is €509.9 m.

  • What is Evotec revenue per employee?

    Latest Evotec revenue per employee is €142.8 k.

  • Who are Evotec competitors?

    Competitors of Evotec include Eurofins, WuXi Biologics and Actelion Pharmaceuticals.

  • Where is Evotec headquarters?

    Evotec headquarters is located at Essener Bogen 7, Hamburg.

  • Where are Evotec offices?

    Evotec has offices in Hamburg, Göttingen, Köln, Planegg and in 8 other locations.

  • How many offices does Evotec have?

    Evotec has 12 offices.